Follow us on Twitter
twitter icon@FreshPatents


G Protein patents

      

This page is updated frequently with new G Protein-related patent applications.




 Methods and compositions for diagnosis and prognosis of renal injury and renal failure patent thumbnailMethods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of clusterin, heart-type fatty acid binding protein, hepatocyte growth factor, interferon gamma, interleukin-12 subunit beta, interleukin-16, interleukin-2, 72 kda type iv collagenase, matrix metalloproteinase-9, midkine, and serum amyloid p-component as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.


 Artificial nucleic acid molecules patent thumbnailArtificial nucleic acid molecules
The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-utr) element comprising a nucleic acid sequence which is derived from the 3′-utr of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
Curevac Ag


 Methods for selecting plants after genome editing patent thumbnailMethods for selecting plants after genome editing
The disclosure provides methods for selecting modified plants with a mutation in a target gene and plants produced by the methods. Specifically, the disclosure provides methods comprising introducing a recombinant expression cassette encoding a genome editing protein into meristematic or germline cells of a parent plant, wherein the genome editing protein specifically recognizes a target gene; crossing or selfing the parent plant, thereby producing a plurality of progeny seeds; and selecting progeny plants grown from the progeny seeds that express a phenotype that can be selected at the intact plant level..
The Regents Of The University Of California


 Development of improved cell-permeable (icp) parkin recombinant protein as a protein-based anti-neurodegenerative agent for the treatment of parkinson's disease-associated phenotypes by utilizing bbb-penetrating protein delivery system mitt, enabled by advanced macromolecule transduction domain (amtd) patent thumbnailDevelopment of improved cell-permeable (icp) parkin recombinant protein as a protein-based anti-neurodegenerative agent for the treatment of parkinson's disease-associated phenotypes by utilizing bbb-penetrating protein delivery system mitt, enabled by advanced macromolecule transduction domain (amtd)
Macromolecule intracellular transduction technology based on improved cell-permeable parkin recombinant protein (icp-parkin) has been developed as a protein-based anti-neurodegenerative agent for efficient bbb-penetration to effectively deliver the recombinant protein into the brain. Parkin protein, a dopaminergic neuronal cell death inhibitor, has been fused with a newly developed advanced macromolecule transduction domain (amtd) and solubilization domain (sd) to increase the solubility/yield and cell-/tissue-permeability of the recombinant protein.
Cellivery Therapeutics, Inc.


 Temperature-responsive cell culture substrate and  producing same patent thumbnailTemperature-responsive cell culture substrate and producing same
Provided is a cell culture substrate, in which polymer (b) having a lower critical solution temperature contained in the substrate is a copolymer of a monomer (a) that becomes a hydrophobic polymer in homopolymerization and a monomer (b, c or d) that becomes a hydrophilic polymer in homopolymerization, which is uncrosslinked, and the lower critical solution temperature of the obtained copolymer (b) can be controlled widely by the types and ratio of the two monomers, to easily detach the cultured cells from the culture substrate surface rapidly without using protein hydrolase and collect the cells without damage. This cell culture substrate contains a polymer (a) of a (meth)acrylic acid ester monomer (a), one or more types of inorganic materials (c) selected from a water-swellable clay mineral and silica, and a polymer (b) having a lower critical solution temperature and including a monomer (a) and a monomer (b, c or d)..
Dic Corporation


 Fn14 binding proteins and uses thereof patent thumbnailFn14 binding proteins and uses thereof
The present disclosure provides proteins comprising antibody antigen binding domains that bind to fn14 and uses thereof. The present disclosure also provides methods for treating wasting disorders, such as cachexia..
La Trobe University


 Novel purification process of gonadotropin patent thumbnailNovel purification process of gonadotropin
The present invention provides an improved method for the purification of desired gonadotropin from a crude mixture containing at least one contaminating protein. The process of purification of the desired gonadotropin according to the present invention comprises use of an affinity chromatography as the first column purification step, prior to use of any column chromatography steps for further purification.
Cadila Healthcare Limited


 Ice structuring protein patent thumbnailIce structuring protein
The present invention relates to a nucleic acid construct comprising: a nucleic acid sequence encoding an ice structuring protein (isp) comprising the sequence set out in seq id no: 1 or a sequence at least 80% identical thereto or comprising the sequence set out in amino acids 21 to 261 of seq id no: 1 or a sequence at least 80% identical thereto; and, linked operably thereto, control sequences permitting expression of the nucleic acid sequence in a filamentous fungal host cell. The construct may be used in a method for the production of an isp, wherein the isp is expressed in a filamentous fungal host cell..
Dsm Ip Assets B.v.


 Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a patent thumbnailFusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.


 Methionine analogs and methods of using same patent thumbnailMethionine analogs and methods of using same
Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties.
Bioxiness Pharmaceuticals, Inc.


Cosmetic

A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols.
Restorsea, Llc

Method for detecting protein modifications using specific antibodies

Method, kit and composition for analyzing analytes for modifications using modification site specific antibodies to bind an analyte with his specific modification sites of interest to different dyes simultaneously with an antibody which is specific to the non-modificated analyte binding to another dye to determine the concentration of the analyte for quantification of the modified analyte in the identical sample.. .
Merck Patent Gmbh

Systems and methods for producing a sugar stream

An improved dry grind system and method for producing a sugar stream from grains or similar carbohydrate sources and/or residues, such as for biofuel production. In particular, a sugar/carbohydrate stream, which includes a desired dextrose equivalent (de) where de describes the degree of conversion of starch to dextrose (aka glucose) and/or has had removed therefrom an undesirable amount of unfermentable components, can be produced after saccharification and prior to fermentation (or other sugar conversion process), with such sugar stream being available for biofuel production, e.g., alcohol production, or other processes.
Fluid Quip Process Technologies, Llc

Systems and methods for producing a sugar stream

An improved dry grind system and method for producing a sugar stream from grains or similar carbohydrate sources and/or residues, such as for biofuel production. In particular, a sugar/carbohydrate stream, which includes a desired dextrose equivalent (de) where de describes the degree of conversion of starch to dextrose (aka glucose) and/or has had removed therefrom an undesirable amount of unfermentable components, can be produced after saccharification and prior to fermentation (or other sugar conversion process), with such sugar stream being available for biofuel production, e.g., alcohol production, or other processes.
Fluid Quip Process Technologies, Llc

Gitr antigen binding proteins

Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Amgen Inc.

Prolactin receptor binding proteins and uses thereof

The present invention encompasses prlr binding proteins. Specifically, the invention relates to antibodies that are chimeric, cdr grafted and humanized antibodies.
Abbvie Inc.

Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent.
Allergan, Inc.

Liquid formulations of tumor necrosis factor-binding proteins

The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of tnf-binding protein, comprising a tnf-binding protein, a buffer and an isotonicity agent.. .
Ares Trading S.a.

Device for detecting misfolded proteins and methods of use thereof

The present invention relates to diagnostic devices as well as methods of using these devices for detecting proteins of interest associated with diseases or disorders in mammals. In particular, the proteins of interest may be misfolded proteins associated with certain misfolded-protein disorders in mammals including those mammals suspected of or at risk of having such disorders..
Gestvision, Inc.

Protein labeling with cyanobenzothiazole conjugates

The invention provides compounds and methods for site-specifically labeling proteins with cyanobenzothiazole derivatives of formula i. For example, the invention provides methods for labeling the n-terminus of a protein that terminates with a cysteine residue.
Promega Corporation

Novel dna-binding proteins and uses thereof

Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel dna-binding domains, including tale dna-binding domains. Also disclosed are methods of using these novel dna-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences..
Sangamo Biosciences, Inc.

Methods and products for expressing proteins in cells

The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules.
Factor Bioscience Inc.

Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof

The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Amgen Inc.

Cd86 antagonist multi-target binding proteins

This disclosure provides a multi-specific fusion protein composed of a cd86 antagonist binding domain and another binding domain that is an il-10 agonist, an hla-g agonist, an hgf agonist, an il-35 agonist, a pd-1 agonist, a btla agonist, a light antagonist, a gitrl antagonist or a cd40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains.
Aptevo Research And Development Llc

Binding proteins against vegf, pdgf, and/or their receptors

Binding proteins that bind one or more of vegf, pdgf and/or their receptors, including antibodies, cdr-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins..
Abbvie Inc.

Compositions and methods for treating and preventing staphylococcus aureus infections

Antibodies having fab regions that specifically bind to staphylococcus aureus protein a are capable of mediating opsinization of staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein a. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing staphylococcus aureus infections..
Xbiotech, Inc.

Factor viii fusion protein

The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated factor viii molecules fused to a polypeptide such as e.g.
Novo Nordisk A/s

Targeted therapeutics

The present invention relates to compositions, methods and kits for delivery of active agents (x) to cells or tissues that express proteoglycans. More specifically, the present invention relates to conjugates comprising (hb-linker)n-xm-(linker-hb)o, where hb is a heparin binding protein, x is an active agent such as a therapeutic protein (including a functional fragment or variant thereof), or a therapeutic small molecule, linker is a linker entity and m is an integer of at least 1, and n+o is an integer of at least 1.
The Brigham And Women's Hospital, Inc.

Long acting proteins and peptides and methods of making and using the same

Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer ifn-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to ifn-γ, particularly via a free cysteine in the protein.
Bolder Biotechnology, Inc.

Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease

The present invention relates to compositions and methods for preparing splice variants of tnfalpha receptor (tnfr) in vivo or in vitro, and the resulting tnfr protein variants. Such variants may be prepared by controlling the splicing of pre-mrna molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (ssos).
Roche Innovation Center Copenhagen A/s

Compositions and methods of preparing leptospira

The present invention includes compositions and methods of preparing flagellar-coiling protein 1 (fcp1)-deficient leptospira bacterium. In one aspect, the invention includes an isolated, flagellar-coiling protein 1 (fcp1)-deficient leptospira bacterium.
Yale University

Igfbp7 for diagnosing diastolic dysfunction

The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of igfbp7 (insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level.
Roche Diagnostics Operations, Inc.

Method for detecting protein-protein interaction

Determining an interaction between the first protein and the second protein according to the detection of the fluorescent focus.. .

Ager-peptides and use thereof

The present invention relates to the identification, functionality and use of domains from the n terminus of the receptor for advanced glycation end products (ager). These domains, called receptor mulitimerization epitope (rme), are highly conserved in all ager protein sequences.
Abbvie Deutschland Gmbh & Co. Kg

Oncostatin m receptor antigen binding proteins

The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. Osmr antigen binding proteins interfere with binding of osm and/or il-31 to osmr.
Kiniksa Pharmaceuticals, Ltd.

Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a

The present invention provides compositions and methods which involve specifically antagonizing gdf8 and activin a. In certain embodiments, compositions are provided which comprise a gdf8-specific binding protein and an activin a-specific binding protein.
Regeneron Pharmaceuticals, Inc.

Fusion proteins comprising igg2 hinge domains

The present invention relates to biologically active fusion proteins containing the igg2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.. .
Gliknik Inc.

Uses of diazepane derivatives

The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.



G Protein topics:
  • Antibodies
  • Nucleic Acid
  • G Proteins
  • Nucleic Acids
  • Amino Acid
  • Polypeptide
  • Protein A Affinity Chromatography
  • Chromatography
  • Chromatograph
  • Liver Metastasis
  • Membrane Protein
  • Colorectal Carcinoma
  • Rectal Carcinoma
  • Prophylactic
  • Glycoprotein


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.0056

    file did exist - file did put2443

    3 - 1 - 54